Prestige Consumer Healthcare Inc. · NYSE:PBH
Prestige Consumer Healthcare — J.P. Morgan Global Leveraged Finance Conference 2026
28 slides from Prestige Consumer Healthcare's conference presentation, Mar 2, 2026
Slide 1: J.P. Morgan Global Leveraged Finance Conference
March 2, 2026 J.P. Morgan Global Leveraged Finance Conference
Slide 2: Safe Harbor Disclosure
Safe Harbor Disclosure This presentation contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company’s expected financial performance, including revenues, organic revenue growth, adjusted diluted E
Slide 3: Contents Overview
Contents Overview I. Introduction to Prestige Consumer Healthcare II. Brand-Building Playbook III. Financial Strategy & Capital Allocation IV. The Road Ahead JP MORGAN LEVERAGED FINANCE CONFERENCE 2026 3
Slide 4: I. Introduction to Prestige Consumer Healthcare
I. Introduction to Prestige Consumer Healthcare JP J PMMOOR RGGA AN NL LE EV VE ER RA AGGE ED DF FI NI NA AN NC CE EC COON NF FE ER RE EN NC CE E2 20 02 26 6
Slide 5: Who We Are: Helping Consumers Care for Themselves
Who We Are: Helping Consumers Care for Themselves eye drops per year throat drops for every cold season doses of pain relief per week infections treated annually JP MORGAN LEVERAGED FINANCE CONFERENCE 2026 5
Slide 6: Diversified Portfolio of Leading Consumer Healthcare Brands
Diversified Portfolio of Leading Consumer Healthcare Brands Total Sales by Category Diverse Portfolio of Market-Leading Brands Oral Motion Sickness Care Other Constipation Cough & Cold 9% 1% Rehydration GI 9% Feminine Hygiene Analgesics 23% Vaginal Anti-Fungal 10% Allergy & Redness Relief Dry Eye Re
Slide 7: Proven Strategy Delivers Long-Term Performance
Proven Strategy Delivers Long-Term Performance Proven Ability to Execute Value Creation Strategy 1 Investing for Growth with Proven Brand-Building Playbook 2 Superior Business Attributes Drive Strong Free Cash Flow 3 Scalable & Efficient Platform Enables Capital Allocation Optionality +3.4% +2.4% +8
Slide 8: II. Brand-Building Playbook
II. Brand-Building Playbook JP J PMMOOR RGGA AN NL LE EV VE ER RA AGGE ED DF FI NI NA AN NC CE EC COON NF FE ER RE EN NC CE E2 20 02 26 6
Slide 9: Brand-Building Focus Positions Us for Long-Term Growth
Brand-Building Focus Positions Us for Long-Term Growth 1 Understanding Consumer Insights and Opportunity 2 Flexible & Agile Brand Strategies in a Dynamic Environment 3 Expanding Consumer Reach and Growth Through E-Commerce Expansion 4 Consumer-Driven New Product Development Resulting Long-Term Succe
Slide 10: Dramamine: Thinking Beyond Motion Sickness
Dramamine: Thinking Beyond Motion Sickness Broadened Motion Sickness Offering Expanding an Iconic Brand into Nausea & Beyond Robust Digital Campaigns Supporting Brand 2011 New Forms & Flavors #1 Brand* in Motion Sickness Leading brand* in Nausea/Motion Sickness Successful Brand-building Resulting in
Slide 11: DenTek: Brand-Building through Iconic Campaigns
DenTek: Brand-Building through Iconic Campaigns Dental Guards – A Strategic Focus Area Agile Marketing Playbook Accelerating Growth Private label 50%+ Market Share* #2 brand Social Media National Sponsored Brand PR & Podcasts Sponsorship Others & Influencers TV Video & Ads Earned Media Estimated Gua
Slide 12: Continue to Drive Strong E-Commerce Growth
Continue to Drive Strong E-Commerce Growth E-Commerce as a % of Net Sales* ~16% Engaging ~14% +4x ~11% Content Driving Traffic ~4% & Conversion FY 19 FY 21 FY 23 FY 25 Continued strong performance across E-Commerce business in FY ‘25 Continually Upgrading User Experience *MULO+ Retail sales data and
Slide 13: Innovation Playbook Wide-Ranging to Address Consumer Needs
Innovation Playbook Wide-Ranging to Address Consumer Needs Product Development Initiatives Extend Brand Through Better Consumer Experience or Claims Innovate Through Technology or Forms New Categories Pediatric Oral Stool Mental Expansion Skin Tags Nausea Softener Alertness JP MORGAN LEVERAGED FINAN
Slide 14: Attractive International Business
Attractive International Business Broad Geographic Reach Growing International Presence Proven Revenue Growth Playbook % Int’l Revenue* Key Brands Australia 50%+ Broad 16% Innovation 55% 14% Digital & Asia Retail 10% Marketing 20% ◼ Strategic collaboration with Europe Strategic long-term broker part
Slide 15: III. Financial Strategy & Capital Allocation
III. Financial Strategy & Capital Allocation JP J PMMOOR RGGA AN NL LE EV VE ER RA AGGE ED DF FI NI NA AN NC CE EC COON NF FE ER RE EN NC CE E2 20 02 26 6
Slide 16: Robust Free Cash Flow Supports Value-Enhancing Capital Allocation
Robust Free Cash Flow Supports Value-Enhancing Capital Allocation Adj. FY Free Cash Flow(2) & Net Leverage(3) Capital Allocation Highlights Manageable 2.6x Net Leverage(3) as of 12/31 $254 $239 $243 $222 $213 $155 million in share repurchases in FY25 YTD 4.2x 3.8x Closed Pillar5 acquisition in Q3 fo
Slide 17: Disciplined Capital Allocation Priorities Unchanged
Disciplined Capital Allocation Priorities Unchanged Organic Long-Term Algorithm… 1 Invest in Current Brands to Drive Organic Growth 2 Pursue M&A That is Attractive to Shareholders Ample Capacity to Pursue Brands & Portfolios of Scale Anticipate approximately $1 billion total Free Cash Flow(2) over t
Slide 18: M&A: Significant Capacity Supports Continued Opportunity
M&A: Significant Capacity Supports Continued Opportunity Consumer Healthcare is Fragmented Plentiful M&A Debt Capacity* 100% Example 80% Categories 60% Show Average Market Share 40% 20% 51% 50% 35% 2.6x Net 21% for Largest Brands Lower in 0% Shampoos Laundry Eye Care Digestives Leverage(3) OTC1 Care
Slide 19: IV. The Road Ahead
IV. The Road Ahead JP J PMMOOR RGGA AN NL LE EV VE ER RA AGGE ED DF FI NI NA AN NC CE EC COON NF FE ER RE EN NC CE E2 20 02 26 6
Slide 20: Continued Line of Sight Into Eye Care Recovery
Continued Line of Sight Into Eye Care Recovery Eye Care Strategic Actions Executed Strategic Priorities for Calendar 2026 ◼ Invest to accelerate Pillar5 production capacity, Added two additional 3rd party suppliers in Q1 and particularly on new high-speed line Q3, respectively, providing substantial
Slide 21: FY 26 Outlook
FY 26 Outlook ◼ Expected revenue decline due largely to eye care supply constraints in first half ◼ Benefitting from well-diversified portfolio and brand-building playbook Top Line Trends ◼ Revenues of approximately $1,100 — Expected organic revenue down approximately 3.0% — Anticipate improvement i
Slide 22: Robust Long-term Growth Algorithm Unchanged
Robust Long-term Growth Algorithm Unchanged Organic Long-Term Algorithm High Proven & Organic Growth(1) Free Cash Flow(2) Repeatable M&A of 2.0% to 3.0% Generation Strategy Current Leverage Supports Additional 6.0% to 8.0% EPS Growth Upside Potential Value Creating Capital Allocation Optionality Pro
Slide 23: Portfolio & Strategy Well-Positioned for Long-Term Value Creation
Portfolio & Strategy Well-Positioned for Long-Term Value Creation 1 Diversified Portfolio of Leading, Trusted Brands 2 Established Organic Growth Brand-Building Playbook 3 Superior Financial Profile Generating Consistent Free Cash Flow 4 Scalable Platform 5 Organic Growth Reinforced by Proven & Repe
Slide 24: Appendix / Q&A
Appendix / Q&A JP MORGAN LEVERAGED FINANCE CONFERENCE 2026
Slide 25: Appendix
Appendix (1) Organic Revenue is a Non-GAAP financial measure and is reconciled to the most closely related GAAP financial measures in the attached Reconciliation Schedules and / or our earnings release dated February 5, 2026 in the “About Non-GAAP Financial Measures” section. (2) EBITDA & EBITDA Mar
Slide 26: Reconciliation Schedules
Reconciliation Schedules Organic Revenue Year Ended March 31, 2025 2020 (In Millions) GAAP Total Revenues $ 1,137.8 $ 963.1 Revenue Change CAGR 3.4% Adjustments: Impact of foreign currency exchange rates (0.1%) Impact of acquisitions & divestitures(a) (0.9%) Total Adjustments (1.0%) Non-GAAP Organic
Slide 27: Reconciliation Schedules (Continued)
Reconciliation Schedules (Continued) Adjusted Net Income & Adjusted EPS Year Ended March 31, 2025 2020 Adjusted Adjusted Net Income EPS Net Income EPS (In Thousands, except per share data) GAAP Net Income (Loss) and Diluted EPS $ 214,605 $ 4.29 $ 142,281 $ 2.78 Adjustments: Transition & other costs
Slide 28: Reconciliation Schedules (Continued)
Reconciliation Schedules (Continued) Adjusted Free Cash Flow 2021 2022 2023 2024 2025 (In Thousands) GAAP Net Income $ 164,682 $ 205,381 $ (82,306) $ 209,339 $ 214,605 Adjustments Adjustments to reconcile net income (loss) to net cash provided by operating activities as shown in the Statement of Cas
Prestige Consumer Healthcare — J.P. Morgan Global Leveraged Finance Conference 2026 on 6ix